Status and phase
Conditions
Treatments
About
Insufficient energy intake and systematic inflammation lead to malnutrition in patients with chronic obstructive pulmonary disease (COPD). Nutritional supplementation improves the patients'nutritional status by increasing energy intake and providing anti-inflammatory elements,which can relieve the patients' symptoms and delay the disease progression.
Full description
Malnutrition is very common in patients with COPD. The main reasons include short intake of energy and systematic inflammation. In our randomized and controlled clinical trial, patients will be divided into two groups: the experimental group and the control group. Patients in the experimental group will be provided nutritional supplements in addition to usual diet every day for three months and patients in the controlled group with usual diet. According to the changes of patients' body composition, anthropometrics, inflammatory markers, lung function, respiratory muscle function, exercise capacity, degree of dyspnea and health related quality of life(HRQL) after intervention,the nutritional status and inflammation status are assessed, which contributes to the prediction of prognosis. The nutritional supplements is a kind of oral liquid composed of proteins, omega-3 fatty acids, carbohydrate, vitamins, which provides about 260 kcal energy per 200ml. The patients from the interventional group need drink the nutritional supplements according to the estimated energy intake and a record should be made everyday. The patients will be followed up regularly by the researcher.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Patients from Zhujiang Hospital affiliated from Southern Medical University
Patients aged between 40 and 90 years old
Patients gendered into male or female
Patients with pulmonary function test of FEV1/FVC<70% and FEV1<80% predicted
Patients presenting one or more of the following situations of malnutrition or nutritional risk: BMI <21 kg/m2 (or<23 kg/m2 in patients ≥ 65); unintentional weight loss >10% in the past 6 months; unintentional weight loss >5% in last month; FFMI <15 kg/m2 (women) or <16 kg/m2 (men)
Patients able to answer question
Patient able to eat and drink
Patients who signed informed consent
Exclusion criteria
Patients with signs of an airway infection
Patients with malignant disorders
Patients with recent surgery
Patients with gastrointestinal ,cardiovascular diseases,neurological diseases or endocrine disease
Patients with bullae lung
patients treated with oral steroids or immunosuppressors
Patients requiring other nutritional supplements or parenteral nutrition
Patients suffering from acute exacerbation over the previous 4 weeks
Patients with lack of motivation or poor compliance
Primary purpose
Allocation
Interventional model
Masking
100 participants in 2 patient groups
Loading...
Central trial contact
Liqing Wang, doctor
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal